Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | The current treatment landscape in CLL

Parag Jasani • 10 Dec 2022
ASH 2022
Chronic Lymphocytic Leukemia Leukemia Antibodies

Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College London Hospital, London, UK, gives an overview of currently available drugs and drug combinations in chronic lymphocytic leukemia (CLL), highlighting their impact on patient outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Parag Jasani

0:56
Personalizing CLL therapy in the frontline
Parag Jasani • 10 Dec 2023
1:29
NVG-111, a ROR1 targeting bispecific TCE, in R/R CLL and MCL: a proof of concept Phase I study
Parag Jasani • 10 Dec 2023
0:58
Phase I trial of NVG-111, a ROR1-targeting BiTE alone or with ibrutinib in R/R CLL & MCL
Parag Jasani • 10 Dec 2022
0:44
The evolution of treatment for elderly patients with CLL
Parag Jasani • 10 Dec 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals